Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

High Rupee Hurts Dr. Reddy Profit; Cipla's Net Rises (India)

This article was originally published in PharmAsia News

Executive Summary

Dr. Reddy's Laboratories Ltd. reports fiscal second-quarter net profit fell 4.5 percent, while Cipla Ltd. says its net profit rose 6.1 percent and forecast a difficult fiscal year coming up. Both firms were affected by the rising rupee. Dr. Reddy's consolidated net profit fell to 2.67 billion rupees ($67.4 million) for the period ended Sept. 30 from 2.8 billion rupees a year earlier, which was boosted by high-margin authorized generic drugs and product exclusivity. Besides the rupee, which has increased more than 10 percent against the dollar since January, Dr. Reddy's blamed costs and revenue from its Betapharm unit, which it acquired last year, for its weak performance. Cipla's net profit rose to 1.91 billion rupees from 1.80 billion rupees, with net sales increasing 23 percent to 10.98 billion rupees. "I will not be too optimistic about the next two quarters," said Joint Managing Director Amar Lulla. "Achieving an annual growth rate of 12 percent to 15 percent will be difficult given the way the rupee is appreciating." (Click here for more - May Require Paid Subscription
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065731

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel